Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
Koichi Takayama(Kyoto Prefectural University of Medicine), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Akira Yamada(Fujita Health University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masanori Noguchi(Kurume University), Shinzo Takamori(Kurume University), Yasuo Saijo(Ho Chi Minh City International University), Shunichi Sugawara(Sendai Kousei Hospital), Tatsuyuki Kakuma(Kurume University), Taishi Harada(Fukuyama City Hospital), Atsushi Satō(National Cancer Center Hospital East), Tetsuro Sasada(Kanagawa Prefectural Hospital Organization), Kyogo Itoh(Kurume University), Junji Kishimoto(Kyushu University Hospital)
Cited by 25
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695